Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alpha for HBsAg Loss in Low Replicative Chronic HBV
NCT02908763Phase 4Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2016
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: HBsAg Clearance Rate at 96 weeks. Status: unknown.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02908763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908763.